10:34:56 EST Mon 17 Nov 2025
Enter Symbol
or Name
USA
CA



Caris Life Sciences to Attend Q4 2025 Investor Conferences

2025-11-17 08:30 ET - News Release

Caris Life Sciences to Attend Q4 2025 Investor Conferences

PR Newswire

IRVING, Texas, Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will attend the following investor conferences:

Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

  • Wolfe Research's 7th Annual Healthcare Conference: New York City, New York
    • Investor meetings: November 18
  • Citi's 2025 Global Healthcare Conference: Miami, Florida
    • Investor meetings: December 3
  • 8th Annual Evercore Healthcare Conference: Miami, Florida
    • Investor meetings: December 4

Contact IR@CarisLS.com to schedule meetings.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition.  Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Caris Life Sciences Media:  
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

Investor Relations:
IR@CarisLS.com
917.689.3511

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-attend-q4-2025-investor-conferences-302616558.html

SOURCE Caris Life Sciences

© 2025 Canjex Publishing Ltd. All rights reserved.